Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $22 price target on Akebia after its Q4 results, saying that while its commercial side of business saw some “snags”, its other vadadustat catalysts were on track and with guidance. The analyst notes that investors should be patient while the “management works through Auryxia’s CMS and DaVita Rx headwinds” look for improved execution in the quarters ahead.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.